patients with milder disease may be adequately treated with 20 mg/kg/day.
in addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.
based on oral dosing data there is an age- or fever- related change in volume of distribution for ibuprofen.
however, because bleeding has been reported when motrin tablets and other nsaids have been administered to patients on warfarin-type anticoagulants, the physician should be cautious when administering motrin tablets to patients on anticoagulants.
hepatic effects borderline elevations of one or more liver tests may occur in up to 15% of patients taking nsaids including motrin suspension.
this may be due to fluid retention, occult or gross gi blood loss, or an incompletely described effect upon erythropoiesis.
a patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with motrin suspension.
there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cv thrombotic events associated with nsaid use.
methotrexate nsaids have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
the duration of fever reduction is generally 6 to 8 hours.
in vivo and in vitro studies indicate that the [+]s-isomer is responsible for clinical activity.
these serious events may occur without warning.
therefore, treatment with motrin suspension is not recommended in these patients with advanced renal disease.
warfarin several short-term controlled studies failed to show that motrin tablets significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on warfarin-type anticoagulants.
motrin suspension cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency.
although it is probably more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease.
renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.
advanced renal disease no information is available from controlled clinical studies regarding the use of motrin suspension in patients with advanced renal disease.
studies in febrile children have established the dose-proportionality of 5 and 10 mg/kg doses of ibuprofen.
laboratory tests because serious gi tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of gi bleeding.
therefore, administration of motrin suspension is not recommended during labor and delivery.
clinical studies - controlled clinical trials comparing doses of 5 and 10 mg/kg ibuprofen suspension and 10-15 mg/kg of acetaminophen elixir have been conducted in children 6 months to 12 years of age with fever primarily due to viral illnesses.
patients with known cv disease or risk factors for cv disease may be at greater risk.
one fever study showed that, after the initial dose of motrin suspension, subsequent doses may be lowered and still provide adequate fever control.
therefore, when treating patients with 3200 mg/day, the physician should observe sufficient increased clinical benefits to offset potential increased risk.
motrin suspension may be used in combination with gold salts and/or corticosteroids.
these events can occur at any time during use and without warning symptoms.
ibuprofen is well absorbed orally, with less than 1% being excreted in the urine unchanged.
adults primary dysmenorrhea: for the treatment of primary dysmenorrhea, beginning with the earliest onset of such pain, motrin suspension should be given in a dose of 400 mg every 4 hours, as necessary, for the relief of pain.
children ingesting 200 to 400 mg/kg of ibuprofen should have immediate gastric emptying and at least four hours observation in a health care facility.
in pediatric patients, motrin suspension is indicated: for reduction of fever in patients aged 6 months up to 2 years of age.
the use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal.
abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, fluid retention, gastrointestinal experiences (including abdominal pain, bloating, constipation, diarrhea, dyspepsia, epigastric pain, flatulence, heartburn, nausea, vomiting), headaches, increased bleeding time, nervousness, pruritus, rashes (including maculopapular) and tinnitus.
to minimize the potential risk for an adverse gi event in patients treated with an nsaid, the lowest effective dose should be used for the shortest possible duration.
this may indicate that they could enhance the toxicity of methotrexate.
as with other nsaids, anaphylactoid reactions may occur in patients without known prior exposure to motrin suspension.
however, because bleeding has been reported when motrin tablets and other nsaids have been administered to patients on warfarin-type anticoagulants, the physician should be cautious when administering motrin tablets to patients on anticoagulants.
ingestion of less than 100 mg/kg is unlikely to produce toxicity.
this risk may increase with duration of use.
it is practically insoluble in water (<0.1 mg/ml), but readily soluble in organic solvents such as ethanol and acetone.
overdosage the toxicity of ibuprofen overdose is dependent upon the amount of drug ingested and the time elapsed since ingestion, though individual response may vary, which makes it necessary to evaluate each case individually.
to minimize the potential risk for an adverse cv event in patients treated with an nsaid, the lowest effective dose should be used for the shortest duration possible.
the duration of fever reduction is generally 6 to 8 hours.
cardiovascular toxicity, including hypotension, bradycardia, tachycardia and atrial fibrillation, also have been reported.
the mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.
motrin suspension, like other nsaids, can cause gi discomfort and, rarely, serious gi side effects, such as ulcers and bleeding, which may result in hospitalization or even death.
to minimize the potential risk for an adverse cv event in patients treated with an nsaid, the lowest effective dose should be used for the shortest duration possible.
other central nervous system symptoms include headache, tinnitus, cns depression and seizures.
diabetics motrin suspension contains 0.3 g sucrose and 1.6 calories per ml, or 1.5 g sucrose and 8 calories per teaspoon, which should be taken into consideration when treating diabetic patients with this product.
metabolism - following oral administration, the majority of the dose was recovered in the urine within 24 hours as the hydroxy-(25%) and carboxypropyl-(37%) phenylpropionic acid metabolites.
most spontaneous reports of fatal gi events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.
although serious gi tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms including epigastric pain, dyspepsia, melena, and hematemesis.
nsaids inhibit platelet aggregation and have been shown to prolong bleeding time in some patients.
therefore, when treating patients with 3200 mg/day, the physician should observe sufficient increased clinical benefits to offset potential increased risk.
after observing the response to initial therapy with motrin suspension, the dose and frequency should be adjusted to suit an individual patient's needs.
use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (seewarnings).
all nsaids, both cox-2 selective and nonselective, may have a similar risk.
the concurrent use of aspirin and an nsaid does increase the risk of serious gi events (seegi warnings).
positive stool occult blood tests and elevated serum creatinine levels were also observed in these studies.
patients with aprior history of peptic ulcer disease and/or gastrointestinal bleeding who use nsaids have a greater than 10-fold risk for developing a gi bleed compared to patients with neither of these risk factors.
aseptic meningitis aseptic meningitis, with fever and coma, has been observed on rare occasions in patients on ibuprofen therapy.
the percentages of free and conjugated ibuprofen found in the urine were approximately 1% and 14%, respectively.
a patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with motrin suspension.
this may be due to fluid retention, occult or gross gi blood loss, or an incompletely described effect upon erythropoiesis.
motrin suspension may be used in combination with gold salts and/or corticosteroids.
children ingesting greater than 400 mg/kg require immediate medical referral, careful observation and appropriate supportive therapy.
hepatic effects borderline elevations of one or more liver tests may occur in up to 15% of patients taking nsaids including motrin suspension.
abrupt discontinuation of corticosteroids may lead to disease exacerbation.
after observing the response to initial therapy with motrin suspension, the dose and frequency should be adjusted to suit an individual patient's needs.
patients with known cv disease or risk factors for cv disease may be at greater risk.
in children with baseline temperatures at or below 102.5°f both ibuprofen doses and acetaminophen were equally effective in their maximum effect.
diuretics clinical studies, as well as post marketing observations, have shown that motrin suspension can reduce the natriuretic effect of furosemide and thiazides in some patients.
these serious adverse events can occur at any time, with or without warning symptoms, in patients treated with nsaids.
since cross reactivity, including bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, motrin suspension should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.
in children with temperatures above 102.5°f, the ibuprofen 10 mg/kg dose was more effective.
the treatment of acute ibuprofen overdose is primarily supportive.
if motrin suspension therapy must be initiated, close monitoring of the patient's renal function is advisable.
in children, the estimated amount of ibuprofen ingested per body weight may be helpful to predict the potential for development of toxicity although each case must be evaluated.
mechanism of action clinical pharmacology pharmacodynamics - ibuprofen is a nonsteroidal anti-inflammatory drug (nsaid) that possesses anti-inflammatory, analgesic and antipyretic activity.
the pharmacological activity of motrin suspension in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
its molecular formula is c13h1802 and it has the following structural formula: motrin suspension is a sucrose-sweetened, orange colored, berry flavored suspension containing 100 mg of ibuprofen in 5 ml (20 mg/ml).
in rat studies with nsaids, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred.
ipecac-induced emesis is not recommended in overdoses greater than 400 mg/kg because of the risk for convulsions and the potential for aspiration of gastric contents.
patients should be informed of the signs of an anaphylactoid reaction (e.g. difficulty breathing, swelling of the face or throat).
in addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.
two large, controlled, clinical trials of a cox-2 selective nsaid for the treatment of pain in the first 10-14 days following cabg surgery found an increased incidence of myocardial infarction and stroke (seecontraindications).hypertension nsaids, including motrin suspension, can lead to onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cv events.
response after 1 hour was dependent on both the level of temperature elevation as well as the treatment.
adults primary dysmenorrhea: for the treatment of primary dysmenorrhea, beginning with the earliest onset of such pain, motrin suspension should be given in a dose of 400 mg every 4 hours, as necessary, for the relief of pain.
two large, controlled, clinical trials of a cox-2 selective nsaid for the treatment of pain in the first 10-14 days following cabg surgery found an increased incidence of myocardial infarction and stroke (seecontraindications).
the [-]r-form, while thought to be pharmacologically inactive, is slowly and incompletely (~60%) interconverted into the active [+]s species in adults.
upper gi ulcers, gross bleeding, or perforation caused by nsaids occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year.
warfarin several short-term controlled studies failed to show that motrin tablets significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on warfarin-type anticoagulants.
it is practically insoluble in water (99% bound at 20μg/ml).
thus, when motrin and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
the use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal.
only one in five patients, who develop a serious upper gi adverse event on nsaid therapy, is symptomatic.
the toxicity of ibuprofen overdose is dependent upon the amount of drug ingested and the time elapsed since ingestion, though individual response may vary, which makes it necessary to evaluate each case individually.
gastrointestinal effects – risk of ulceration, bleeding, and perforation nsaids, including motrin suspension, can cause serious gastrointestinal (gi) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal.
management of hypotension, acidosis and gastrointestinal bleeding may be necessary.
lithium ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
in two postmarketing clinical studies the incidence of a decreased hemoglobin level was greater than previously reported.
in patients with primary dysmenorrhea, ibuprofen has been shown to reduce elevated levels of prostaglandin activity in the menstrual fluid and to reduce testing and active intrauterine pressure, as well as the frequency of uterine contractions.
patients with milder disease may be adequately treated with 20 mg/kg/day.
hypertension nsaids, including motrin suspension, can lead to onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cv events.
metabolic acidosis, coma, acute renal failure and apnea (primarily in very young children) may rarely occur.
in a situation when low fever would require the motrin suspension 5 mg/kg dose in a child with pain, the dose that will effectively treat the predominant symptom should be chosen.
in late pregnancy, as with other nsaids, motrin should be avoided because it may cause premature closure of the ductus arteriosus.
in patients taking motrin or other nsaids, the most frequently reported adverse experiences occurring in approximately 1-10% of patients are: abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, fluid retention, gastrointestinal experiences (including abdominal pain, bloating, constipation, diarrhea, dyspepsia, epigastric pain, flatulence, heartburn, nausea, vomiting), headaches, increased bleeding time, nervousness, pruritus, rashes (including maculopapular) and tinnitus.
severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (seewarnings – anaphylactoid reactions, and precautions – preexisting asthma).
pediatric use safety and effectiveness of motrin suspension in pediatric patients below the age of 6 months have not been established (seeclinical pharmacology - clinical studies).
the excretion of ibuprofen is virtually complete 24 hours after the last dose.
anaphylactoid reactions as with other nsaids, anaphylactoid reactions may occur in patients without known prior exposure to motrin suspension.
the mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.
there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cv thrombotic events associated with nsaid use.
diabetics motrin suspension contains 0.3 g sucrose and 1.6 calories per ml, or 1.5 g sucrose and 8 calories per teaspoon, which should be taken into consideration when treating diabetic patients with this product.
in cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or lavage.
children ingesting 200 to 400 mg/kg of ibuprofen should have immediate gastric emptying and at least four hours observation in a health care facility.
motrin suspension, like other nsaids, may cause serious cv side effects, such as mi or stroke, which may result in hospitalization, and even death.
motrin suspension is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (seewarnings ).
thus, when motrin and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible.
cardiovascular toxicity, including hypotension, bradycardia, tachycardia and atrial fibrillation, also have been reported.
there is no difference in the observed terminal elimination rate or half-life between children and adults, however, there is an age-or fever-related change in total clearance.
these serious events may occur without warning.
if motrin suspension therapy must be initiated, close monitoring of the patient's renal function is advisable.
patients with rheumatoid arthritis seem to require higher doses than do patients with osteoarthritis.
in these studies there were no differences between treatments in fever reduction for the first hour and maximum fever reduction occurred between 2 and 4 hours.
renal effects long-term administration of nsaids has resulted in renal papillary necrosis and other renal injury.
pregnancy reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities.
during concomitant therapy with nsaids, the patient should be observed closely for signs of renal failure (seewarnings, renal effects), as well as to assure diuretic efficacy.
most spontaneous reports of fatal gi events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.
lithium ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
in children, the estimated amount of ibuprofen ingested per body weight may be helpful to predict the potential for development of toxicity although each case must be evaluated.
gastrointestinal effects – risk of ulceration, bleeding, and perforation nsaids, including motrin suspension, can cause serious gastrointestinal (gi) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal.
since cross reactivity, including bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, motrin suspension should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.
children ingesting 100 to 200 mg/kg may be managed with induced emesis and a minimal observation time of four hours.
decrease in hemoglobin of 1 gram or more was observed in 17.1% of 193 patients on 1600 mg ibuprofen daily (osteoarthritis), and in 22.8% of 189 patients taking 2400 mg of ibuprofen daily (rheumatoid arthritis).
ipecac-induced emesis is not recommended in overdoses greater than 400 mg/kg because of the risk for convulsions and the potential for aspiration of gastric contents.
management of hypotension, acidosis and gastrointestinal bleeding may be necessary.
during concomitant therapy with nsaids, the patient should be observed closely for signs of renal failure (seewarnings, renal effects), as well as to assure diuretic efficacy.
individual patients may show a better response to 3200 mg daily, as compared with 2400 mg, although in well-controlled clinical trials patients on 3200 mg did not show a better mean response in terms of efficacy.
nonteratogenic effects because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.
nsaids inhibit platelet aggregation and have been shown to prolong bleeding time in some patients.
orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen.
if clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash, etc.)
the [-]r-isomer serves as a circulating reservoir to maintain levels of active drug.
diuretics clinical studies, as well as post marketing observations, have shown that motrin suspension can reduce the natriuretic effect of furosemide and thiazides in some patients.
metabolic acidosis, coma, acute renal failure and apnea (primarily in very young children) may rarely occur.
patients taking thiazides or loop diuretics may have impaired response to these therapies when taking nsaids.
in late pregnancy, as with other nsaids, motrin suspension should be avoided because it may cause premature closure of the ductus arteriosus.
renal effects long-term administration of nsaids has resulted in renal papillary necrosis and other renal injury.
renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.
in two postmarketing clinical studies the incidence of a decreased hemoglobin level was greater than previously reported.
warnings boxed warning cardiovascular risk nsaids may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal.
because serious gi tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of gi bleeding.
therefore, treatment with motrin suspension is not recommended in these patients with advanced renal disease.
dosing of motrin suspension in children 6 months or older should be guided by their body weight (seedosage and administration).
elderly patients are at greater risk for serious gastrointestinal events (seewarnings).
pediatric use safety and effectiveness of motrin suspension in pediatric patients below the age of 6 months have not been established (seeclinical pharmacology - clinical studies).
other factors that increase the risk for gi bleeding in patients treated with nsaids include concomitant use of oral corticosteroids or anticoagulants, longer duration of nsaid therapy, smoking, use of alcohol, older age, and poor general health status.
children ingesting 100 to 200 mg/kg may be managed with induced emesis and a minimal observation time of four hours.
cardiovascular effects cardiovascular thrombotic events clinical trials of several cox-2 selective and nonselective nsaids of up to three years duration have shown an increased risk of serious cardiovascular (cv) thrombotic events, myocardial infarction, and stroke, which can be fatal.
the pharmacological activity of motrin suspension in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
in patients with juvenile arthritis, doses above 50 mg/kg/day are not recommended because they have not been studied and doses exceeding the upper recommended dose of 40 mg/kg/day may increase the risk of causing serious adverse events.
in a situation when low fever would require the motrin suspension 5 mg/kg dose in a child with pain, the dose that will effectively treat the predominant symptom should be chosen.
gastrointestinal risk nsaids cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
special precautions general motrin suspension cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency.
upper gi ulcers, gross bleeding, or perforation caused by nsaids occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year.
this may indicate that they could enhance the toxicity of methotrexate.
the biological activities of ibuprofen are associated with the [+]s-enantiomer.
one fever study showed that, after the initial dose of motrin suspension, subsequent doses may be lowered and still provide adequate fever control.
unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible.
febrile children <11 years old have a volume of approximately 0.2 l/kg while adults have a volume of approximately 0.12 l/kg.
in these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.
advanced renal disease no information is available from controlled clinical studies regarding the use of motrin suspension in patients with advanced renal disease.
protein binding is saturable and at concentrations >20μg/ml binding is non-linear.
only one in five patients, who develop a serious upper gi adverse event on nsaid therapy, is symptomatic.
the concurrent use of aspirin and an nsaid does increase the risk of serious gi events (seegi warnings).
in these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.
nonteratogenic effects because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.
after absorption of the racemic ibuprofen, the [-]r-enantiomer undergoes interconversion to the [+]s-form.
aseptic meningitis aseptic meningitis, with fever and coma, has been observed on rare occasions in patients on ibuprofen therapy.
clinical trials of several cox-2 selective and nonselective nsaids of up to three years duration have shown an increased risk of serious cardiovascular (cv) thrombotic events, myocardial infarction, and stroke, which can be fatal.
in rat studies with nsaids, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred.
positive stool occult blood tests and elevated serum creatinine levels were also observed in these studies.
emesis is most effective if initiated within 30 minutes of ingestion.
in late pregnancy, as with other nsaids, motrin should be avoided because it may cause premature closure of the ductus arteriosus.
therefore, administration of motrin suspension is not recommended during labor and delivery.
skin reactions nsaids, including motrin suspension, can cause serious skin adverse events such as exfoliative dermatitis, stevens-johnson syndrome (sjs), and toxic epidermal necrolysis (ten), which can be fatal.
emesis is most effective if initiated within 30 minutes of ingestion.
the effects of warfarin and nsaids on gi bleeding are synergistic, such that the users of both drugs together have a risk of serious gi bleeding higher than users of either drug alone.
skin reactions nsaids, including motrin suspension, can cause serious skin adverse events such as exfoliative dermatitis, stevens-johnson syndrome (sjs), and toxic epidermal necrolysis (ten), which can be fatal.
the smallest dose of motrin suspension that yields acceptable control should be employed.
however, even short-term therapy is not without risk.
although it is probably more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease.
severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (seewarnings – anaphylactoid reactions, and precautions – preexisting asthma).
motrin suspension is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (seewarnings ).
pediatric patients fever reduction: for reduction of fever in children, 6 months up to 2 years of age, the dosage should be adjusted on the basis of the initial temperature level (seeclinical pharmacology).
this suggests that the observed change in clearance is due to changes in the volume of distribution of ibuprofen (seetable 1 for cl/f values).
orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen.
although serious cv events can occur without warning symptoms, patients should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms.
if clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, motrin suspension should be discontinued.
preexisting asthma patients with asthma may have aspirin-sensitive asthma.
in control groups treated with 10 mg/kg acetaminophen, fever reduction resembled that seen in children treated with 5 mg/kg of ibuprofen, with the exception that temperature elevation tended to return 1-2 hours earlier.
these laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy.
ingestion of less than 100 mg/kg is unlikely to produce toxicity.
these laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy.
drug interactions ace-inhibitors reports suggest that nsaids may diminish the antihypertensive effect of ace-inhibitors.
drug interactions reports suggest that nsaids may diminish the antihypertensive effect of ace-inhibitors.
for relief of mild to moderate pain in patients aged 6 months up to 2 years of age.
absorption - in vivo studies indicate that ibuprofen is well absorbed orally from the suspension formulation, with peak plasma levels usually occurring within 1 to 2 hours (seetable 1).
(read circulars for lithium preparation before use of such concurrent therapy.)methotrexate nsaids have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
by 6 hours, children treated with ibuprofen 5mg/kg tended to have recurrence of fever, whereas children treated with ibuprofen 10 mg/kg still had significant fever reduction at 8 hours.
patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritis, jaundice, right upper quadrant tenderness, and "flu-like" symptoms).
children ingesting greater than 400 mg/kg require immediate medical referral, careful observation and appropriate supportive therapy.
the effects of warfarin and nsaids on gi bleeding are synergistic, such that the users of both drugs together have a risk of serious gi bleeding higher than users of either drug alone.
however, even short-term therapy is not without risk.
individual patients may show a better response to 3200 mg daily, as compared with 2400 mg, although in well-controlled clinical trials patients on 3200 mg did not show a better mean response in terms of efficacy.
pediatric patients fever reduction: for reduction of fever in children, 6 months up to 2 years of age, the dosage should be adjusted on the basis of the initial temperature level (seeclinical pharmacology).
the remainder of the drug was found in the stool as both metabolites and unabsorbed drug.
patients with aprior history of peptic ulcer disease and/or gastrointestinal bleeding who use nsaids have a greater than 10-fold risk for developing a gi bleed compared to patients with neither of these risk factors.
additional adverse experiences reported occasionally include: body as a whole - fever, infection, sepsis cardiovascular system - congestive heart failure in patients with marginal cardiac function, hypertension, tachycardia, syncope digestive system - dry mouth, duodenitits, esophagitis, gastric or duodenal ulcer with bleeding and/or perforation, gastritis, gastrointestinal bleeding, glossitis, hematemesis, hepatitis, jaundice, melena, rectal bleeding hemic and lymphatic system - ecchymosis, eosinophilia, leukopenia, purpura, stomatitis, thrombocytopenia metabolic and nutritional - weight changes nervous system - anxiety, asthenia, confusion, depression, dream abnormalities, drowsiness, insomnia, malaise, paresthesia, somnolence, tremors, vertigo respiratory system - asthma, dyspnea skin and appendages - alopecia, photosensitivity, sweat special senses - blurred vision urogenital system - cystitis, dysuria, hematuria, interstitial nephritis, oliguria/polyuria, proteinuria, acute renal failure in patients with pre-existing significantly impaired renal function other adverse reactions, which occur rarely are: body as a whole - anaphylactic reactions, anaphylactoid reactions, appetite changes, cardiovascular system - arrhythmia, cerebrovascular accident, hypotension, myocardial infarction, palpitations, vasculitis digestive system - eructation, gingival ulcer, hepatorenal syndrome, liver necrosis, liver failure, pancreatitis hemic and lymphatic system - agranulocystosis, hemolytic anemia, aplastic anemia, lymphadenopathy, neutropenia, pancytopenia metabolic and nutritional - hyperglycemia nervous system - convulsions, coma, emotional lability, hallucinations, aseptic meningitis respiratory - apnea, respiratory depression, pneumonia, rhinitis skin and appendages - angioedema, toxic epidermal necrosis, erythema multiforme, exfoliative dermatitis, stevens johnson syndrome, urticaria, vesiculobullous eruptions special senses - amblyopia (blurred and/or diminished vision, scotomata and/or changes in color vision), conjunctivitis, dry eyes, hearing impairment urogenital- azotemia, decreased creatinine clearance, glomerulitis, renal papillary necrosis, tubular necrosis description
patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (seewarnings).
motrin suspension, like other nsaids, can cause serious skin side effects such as exfoliative dermatitis, sjs, and ten, which may result in hospitalizations and even death.
use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (seewarnings).
in patients with juvenile arthritis, doses above 50 mg/kg/day are not recommended because they have not been studied and doses exceeding the upper recommended dose of 40 mg/kg/day may increase the risk of causing serious adverse events.
patients with rheumatoid arthritis seem to require higher doses than do patients with osteoarthritis.
patients taking thiazides or loop diuretics may have impaired response to these therapies when taking nsaids.
other factors that increase the risk for gi bleeding in patients treated with nsaids include concomitant use of oral corticosteroids or anticoagulants, longer duration of nsaid therapy, smoking, use of alcohol, older age, and poor general health status.
decrease in hemoglobin of 1 gram or more was observed in 17.1% of 193 patients on 1600 mg ibuprofen daily (osteoarthritis), and in 22.8% of 189 patients taking 2400 mg of ibuprofen daily (rheumatoid arthritis).
in cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or lavage.
the smallest dose of motrin suspension that yields acceptable control should be employed.
other central nervous system symptoms include headache, tinnitus, cns depression and seizures.
these serious adverse events can occur at any time, with or without warning symptoms, in patients treated with nsaids.
pregnancy teratogenic effects – pregnancy category c reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities.
abrupt discontinuation of corticosteroids may lead to disease exacerbation.
to minimize the potential risk for an adverse gi event in patients treated with an nsaid, the lowest effective dose should be used for the shortest possible duration.
